现货，Brivanib (BMS-540215)，目录号S1084，CAS号:649735-46-6, 受体酪氨酸激酶(RTK)，VEGFRYZ剂，美国Selleck_详细资料

产品信息 保存条件：零下二十摄氏度低温干燥保存供应商：赛导通生物科技保质期：两年英文名： Brivanib (BMS-540215) CAS号： 649735-46-6 数量：大量规格： 5mg 信号转导通路:  受体酪氨酸激酶(RTK) >> VEGFR >> VEGFR YZ剂 >> Brivanib (BMS-540215) 网站链接：http://selleck.cn/brivanib-S1084.html 技术数据: 分子量(MW): 370.38 化学式: C₁₉H₁₉FN₄O₃ 溶解度: DMSO ≥74mg/mL   Water <1mg/mL   Ethanol ≥5mg/mL 纯度: >99% 稳定性: at -20℃ 2 years CAS号: 649735-46-6 生物活性 Brivanib 是ATP竞争性YZ剂，作用于人类VEGFR-2时IC50 为25 nM。Brivanib也强YZ鼠类Flk-1，IC50为89nM。而Brivanib对 PDGFR-β, EGFR, LCK, PKCα ，及JAK-3YZ效果不大，IC50值都大于1900 nM。体外研究时显示Brivanib YZVEGF-刺激的-HUVECs，IC50为40 nM。Brivanib作用于胸腺缺陷鼠的H3396移植瘤时显示出活性。按鼠体重，每千克分别口服处理60 和90 mg Brivanib，肿瘤生长完全被YZ，而肿瘤生长YZ率分别达到85% 和97% ^[1]Brivanib作用于肝癌移植瘤，VEGFR-2的磷酸化作用下降，导致肿瘤生长明显被YZ。结果显示与对照组按鼠体积每千克分别处理50mg和100mg时相比，06-0606移植瘤鼠的肿瘤体重分别为55%和13%。Brivanib作用于肝癌时效果显著。[2]Brivanib目前处于二期到三期临床实验阶段，BrivanibZ初是由Bristol-Myers Squibb制药公司研究的。 参考文献 [1] Bhide RS, et al. J Med Chem, 2006, 49 (7), 2143-2146. [2] Huynh, H., et al. Clin Cancer Res, 2008,14 (19), 6146-6153. 客户反馈数据 For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Brivanib by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells. 如果需要长期保存，请于零下二十度低温保存。 禁止用于人体及ZL！ 特定的存储和包装每个产品的信息在产品说明书上都有注明。大多数Selleck产品，在推荐的条件下存储可稳定保存两年。产品有时建议的储存温度不同，大多数建议储存在-20 ° C ，抗体及蛋白等产品建议-60℃。YZ剂属于化学试剂，可在常温下运输储存两周左右。即使如此，我们保证产品的出货量将保持产品质量的条件下，一般都会放入冰袋。望阁下收到产品后，请按照产品数据表建议适当存储。 退换货政策 1、退换货只针对已付款用户。一张订单Selleck只提供一次退换货服务，为了确保您的权益，请考虑周全后与我们联系。 2、请您确保退换货时，商品、配件、赠品及各种包装完整。 3、因您个人原因造成的商品损坏（如自行使用、分装、受潮、变质、非原物品的等）将不予退换。 4、Selleck目前只支持商品一换一服务，换货时无法加定商品。 5、如您购买商品时Selleck上海办事处已向您提供发票，则办理退货或订单金额发生变更的换货时，请将发票随商品一同返还给Selleck上海办事处赛导通生物科技（上海）有限公司，请您妥善保管发票，如发票丢失，将无法办理退换货。 6、您的订单若办理退换货，运费金额会在您的实际退款中扣除。 温馨提示：不可用于临床ZL。

分子量(MW):	370.38
化学式:	C₁₉H₁₉FN₄O₃
溶解度:	DMSO ≥74mg/mL Water <1mg/mL Ethanol ≥5mg/mL
纯度:	>99%
稳定性:	at -20℃ 2 years
CAS号:	649735-46-6

	For MTT assays, cells (2,000 ~ 5,000 cells/well) were subcultured into 96-well plates according to their growth properties. Cell proliferation was assayed at 72 hr after treatment of Brivanib by adding 20 μl of 5 mg/ml 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution per 100 μl of growth medium. After incubating for 3-4 h at 37°C, the media were removed and 150 µl/well of MTT solvent (either absolute DMSO or isopropanol containing 4 mM HCl and 0.1% Nonidet-40) was added to dissolve the formazan. The absorbance of each well was measured by ELx808 (BioTek, Winooski, VT) or Wallac Victor2 (Perkin-Elmer Life Sciences, Boston, MA) Microplate Reader. Viable cells are presented as percent of control, vehicle-treated cells.

您可能感兴趣的产品

现货，Brivanib (BMS-540215)，目录号S1084，CAS号:649735-46-6, 受体酪氨酸激酶(RTK)，VEGFRYZ剂，美国Selleck

产品信息

联系我们

关注我们